AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
AUSTIN, Texas, March 17, 2017 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that it will report its financial results for the quarter and year ended December 31, 2016 on Thursday, March 23 after the market close, and will host a corporate update conference call and webcast at 4:30pm Eastern Time.
Conference Call & Webcast Details
To access the live conference call on Thursday, March 23, 20117 at 4:30 p.m. ET via phone, please dial (888) 503-8175 from the United States or +1 (719) 457-2653 internationally. A replay of the call will be available through April 6, 2017 by dialing (844) 512-2921 from the United States or +1 (412) 317-6671 internationally. The conference call ID is 2242567.
To access the live and archived webcast of the presentation, please visit the Investor Relations section of the Aeglea BioTherapeutics website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary.
About Aeglea BioTherapeutics
Aeglea is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. The company’s engineered human enzymes are designed to modulate the extremes of amino acid metabolism in the blood to reduce toxic levels of amino acids in inborn errors of metabolism or target tumor metabolism for cancer treatment. AEB1102, Aeglea’s lead product candidate, is currently being studied in two ongoing Phase 1 clinical trials in patients with advanced solid tumors and acute myeloid leukemia/myelodysplastic syndrome (AML/MDS). Additionally, Aeglea is recruiting patients into its Phase 1/2 trial of AEB1102 for the treatment of patients with Arginase I deficiency. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine/cystine, and AEB2109, which degrades methionine. For more information, please visit http://aegleabio.com.
Contact: Media Contact: Kelly Boothe, Ph.D. Pure Communications 415.946.1076 [email protected] Investor Contact: Charles N. York II Chief Financial Officer Aeglea BioTherapeutics [email protected]
